Cargando…

Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma

OBJECTIVE: Avelumab (MSB0010718C) is a fully human anti-programmed cell death ligand 1(PD-L1) antibody against PD-L1 interactions and enhances immune activation against tumor cells in the meantime. Avelumab has been approved for locally advanced or metastatic urothelial cancer (mUC) after disease pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Qian, Zheng, Hanrui, Chen, Ye, Peng, Xingchen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9093135/ https://www.ncbi.nlm.nih.gov/pubmed/35570929 http://dx.doi.org/10.3389/fpubh.2022.837854

Ejemplares similares

Corrigendum: Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma
por: Xie, Qian, et al.
Publicado: (2022)

A cost‐effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first‐line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan
por: Su, Po‐Jung, et al.
Publicado: (2023)

Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma
por: Han, Jiaqi, et al.
Publicado: (2023)

Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
por: Tomita, Yoshihiko, et al.
Publicado: (2022)

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
por: Kim, Tae Won, et al.
Publicado: (2016)

Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients
por: Kitazawa, Haruna, et al.
Publicado: (2019)

Chemotherapy Plus Best Supportive Care versus Best Supportive Care in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Zhong, Chenxi, et al.
Publicado: (2013)

A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer
por: Wang, J, et al.
Publicado: (2011)

Best Supportive Care of the Patient with Oesophageal Cancer
por: Pichel, Rita Carrilho, et al.
Publicado: (2022)

Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population
por: Henk, Henry J, et al.
Publicado: (2013)

Job Maintenance by Supported Employment: An Overview of the “Supported Employment Plus” Trial
por: Kawohl, Wolfram, et al.
Publicado: (2015)

Evaluating the Cost-Effectiveness of Proportional-Assist Ventilation Plus vs. Pressure Support Ventilation in the Intensive Care Unit in Two Countries
por: Saunders, Rhodri, et al.
Publicado: (2018)

A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
por: Mubarak, Nabil, et al.
Publicado: (2012)

Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial
por: Nickols, Nicholas G., et al.
Publicado: (2021)

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer
por: Paz-Ares, Luis G, et al.
Publicado: (2010)

Clinical evidence and insights supporting the use of avelumab first‐line maintenance treatment in patients with advanced urothelial carcinoma in the Asia‐Pacific region
por: Eto, Masatoshi, et al.
Publicado: (2022)

Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment
por: Starling, N, et al.
Publicado: (2007)

Healthcare resource utilization and medical costs in patients with terminal cancer during best supportive care
por: Kang, Dong-Won, et al.
Publicado: (2022)

Best Practices for Building and Supporting Effective ACGME-Mandated Program Evaluation Committees
por: Greenfield, Jessica, et al.
Publicado: (2020)

Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer
por: Qin, Shukui, et al.
Publicado: (2021)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
por: De Lorenzo, Stefania, et al.
Publicado: (2018)

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study
por: Chen, Eric X., et al.
Publicado: (2020)

Physical Activity as the Best Supportive Care in Cancer: The Clinician’s and the Researcher’s Perspectives
por: Torregrosa, Cécile, et al.
Publicado: (2022)

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
por: Bullement, Ash, et al.
Publicado: (2019)

A case of pseudoprogression in avelumab maintenance therapy for metastatic bladder cancer
por: Hayakawa, Nozomi, et al.
Publicado: (2022)

Job Maintenance through Supported Employment PLUS: A Randomized Controlled Trial
por: Telle, Nils-Torge, et al.
Publicado: (2016)

A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy.
por: Cascinu, S., et al.
Publicado: (1995)

Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
por: Goswami, Hardik, et al.
Publicado: (2022)

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome
por: Anderson, H, et al.
Publicado: (2000)

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice
por: Grivas, P., et al.
Publicado: (2023)

The need for a re-evaluation of best supportive care studies reported to date
por: Currow, D C, et al.
Publicado: (2011)

Best supportive care in clinical trials: review of the inconsistency in control arm design
por: Nipp, R D, et al.
Publicado: (2015)

Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions
por: Ferrara, Giovanni, et al.
Publicado: (2018)

Maintenance and reliability best practices /
por: Gulati, R. D.
Publicado: (2021)

Best Supportive Care Versus Whole-Brain Irradiation, Chemotherapy Alone, or WBRT Plus Chemotherapy in Patients With Brain Metastases From Small-Cell Lung Cancer: A Case-Controlled Analysis
por: Li, Hongwei, et al.
Publicado: (2021)

Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
por: Goswami, Hardik, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States
por: Ramjee, Lauren, et al.
Publicado: (2023)

Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia
por: Garcia-Manero, Guillermo, et al.
Publicado: (2016)

Best Care Anywhere
por: Longman, Phillip
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_hetn6fa7lll1hh6u6tjj51vlag